2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 716

Utility of Novel Patient-Reported Outcome Instruments in Predicting Cardiac Involvement and Pulmonary Hypertension in Patients with Systemic Sclerosis
Abstract Number: 133

Utility of PET-CT Imaging in IgG4-Related Disease
Abstract Number: 1970

Utility of Spine Bone Mineral Density in Fracture Prediction within the Fracture Risk Assessment Tool (FRAX)
Abstract Number: 2165

Utility of Vectra-DA™ On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response: Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy
Abstract Number: 1834

Utilization and Expected Cost of Rheumatoid Arthritis Patients Treated with Golimumab: A Specialty Pharmacy Perspective
Abstract Number: 2039

Uveitis Surveillance Through Lean-Six Sigma for Quality Assurance in Juvenile Idiopathic Arthritis
Abstract Number: 2412

Valdiation of a Diagnosis of Gout in the Epiccare Electronic Medical Records
Abstract Number: 542

Validation of a Reference Imaging Module for Calibration of Readers Scoring with the Modified Stoke Ankylosing Spondylitis Spine Score
Abstract Number: 1314

Validation of Algorithms Using Genome-Wide SNP Analysis for Prediction of Remission or Low Disease Activity for Infliximab or Etanercept-Treated RA Patients
Abstract Number: 1171

Validation of BASDAI and BASFI in Children with Spondyloarthritis
Abstract Number: 2551

Validation of EULAR Primary Sjögren’s Syndrome Disease Activity and Patient Indexes
Abstract Number: 2118

Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Abstract Number: 288

Validation of Promis Modules for Use in Childhood-Onset Lupus
Abstract Number: 80

Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials
Abstract Number: 1345

Validation of the Health Assessment Questionnaire for Spondyloarthritis in Patients with Non-Radiographic Axial Spondyloarthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].